+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

12-month follow-up after successful infliximab therapy in pediatric crohn disease

12-month follow-up after successful infliximab therapy in pediatric crohn disease

Journal of Pediatric Gastroenterology and Nutrition 46(3): 293-298

Infliximab (IFX) therapy is highly efficacious for the induction and maintenance of remission in pediatric Crohn disease (CD). However, to date it is unclear how long patients should be given IFX. Given the increasing safety concerns about the concomitant and prolonged use of IFX and azathioprine in CD, we wanted to address the clinical outcome in pediatric CD patients who responded to IFX medication, once IFX was stopped. Upon induction therapy with 3 IFX infusions, 36 of 38 patients with CD were in clinical remission at 3 months. These 36 responders were separated into 2 groups: 16 patients received no further IFX infusions, whereas 20 patients received scheduled maintenance therapy with IFX for 12 months. Among the 16 patients who received no further IFX infusions, 12 experienced relapse during the 12-month follow-up interval after IFX was stopped. In the group receiving maintenance therapy, 11 of 20 patients remained in clinical remission at 12 months of therapy, whereas 8 patients required adjustment of IFX doses or intervals. Among the 11 children who were in clinical remission and receiving maintenance therapy without dose adjustment, 8 experienced relapse within 12 months after IFX maintenance therapy was stopped. Overall, the relapse rates after IFX induction or maintenance therapy was stopped were 75% and 72%, respectively. These data indicate that IFX is efficacious in controlling severe pediatric CD; however, to induce and maintain clinical remission, repeated IFX infusions are required, with a need for dose adjustment in a substantial number of patients.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 022130933

Download citation: RISBibTeXText

PMID: 18376247

DOI: 10.1097/mpg.0b013e31815604cd

Related references

A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy. Korean Journal of Gastroenterology 46(4): 297-301, 2005

Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease. Journal of Crohn's and Colitis 8(8): 747-755, 2014

Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterologie Clinique et Biologique 30(2): 247-252, 2006

Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy. Pediatric Radiology 47(8): 924-934, 2017

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up. Pediatric Gastroenterology Hepatology and Nutrition 15(4): 243-249, 2012

Successful infliximab therapy for oral Crohn's disease. Inflammatory Bowel Diseases 12(4): 337-338, 2006

Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflammatory Bowel Diseases 14(3): 353-358, 2008

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. Plos one 10(12): E0144900, 2015

Infliximab therapy for pediatric Crohn's disease. Expert Opinion on Biological Therapy 7(12): 1869-1880, 2007

Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflammatory Bowel Diseases 7(1): 34-37, 2001

Timing infliximab therapy in pediatric Crohn's disease. Gastroenterology 132(3): 1167-1170, 2007

Infliximab therapy in pediatric Crohn's disease: a review. Clinical and Experimental Gastroenterology 3: 57-63, 2010

Successful treatment of therapy-resistant metastatic Crohn's disease with infliximab. British Journal of Dermatology 150(5): 1045-1046, 2004

Successful infliximab therapy for a duodenal stricture caused by Crohn's disease. Inflammatory Bowel Diseases 11(12): 1123-1125, 2005

Infliximab as first-line therapy in severe pediatric Crohn disease. Journal of Pediatric Gastroenterology and Nutrition 43(3): 388-390, 2006